F
Frances Ayres
Researcher at National Health Laboratory Service
Publications - 10
Citations - 1444
Frances Ayres is an academic researcher from National Health Laboratory Service. The author has contributed to research in topics: Neutralization & Antibody. The author has an hindex of 5, co-authored 10 publications receiving 749 citations. Previous affiliations of Frances Ayres include University of the Witwatersrand.
Papers
More filters
Journal ArticleDOI
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.
Constantinos Kurt Wibmer,Frances Ayres,Tandile Hermanus,Mashudu Madzivhandila,Prudence Kgagudi,Brent Oosthuysen,Bronwen E. Lambson,Bronwen E. Lambson,Tulio de Oliveira,Marion Vermeulen,Karin van der Berg,Karin van der Berg,Theresa M. Rossouw,Michael T. Boswell,Veronica Ueckermann,Susan Meiring,Anne von Gottberg,Anne von Gottberg,Cheryl Cohen,Cheryl Cohen,Lynn Morris,Lynn Morris,Jinal N. Bhiman,Jinal N. Bhiman,Penny L. Moore,Penny L. Moore +25 more
TL;DR: In this article, the authors show that SARS-CoV-2 501Y.1.V2 spike protein completely escapes three classes of therapeutically relevant antibodies and exhibits substantial to complete escape from neutralization, but not binding, by convalescent plasma.
Posted ContentDOI
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Constantinos Kurt Wibmer,Frances Ayres,Tandile Hermanus,Mashudu Madzivhandila,Prudence Kgagudi,Brent Oosthuysen,Bronwen E. Lambson,Bronwen E. Lambson,Tulio de Oliveira,Marion Vermeulen,Karin van der Berg,Karin van der Berg,Theresa M. Rossouw,Michael T. Boswell,Veronica Ueckermann,Susan Meiring,Anne von Gottberg,Anne von Gottberg,Cheryl Cohen,Cheryl Cohen,Lynn Morris,Lynn Morris,Jinal N. Bhiman,Jinal N. Bhiman,Penny L. Moore,Penny L. Moore +25 more
TL;DR: SARS-CoV-2 501Y.V2 (B.1.351), a lineage of coronavirus causing COVID-19, contains substitutions in two immunodominant domains of the spike protein this article.
Journal ArticleDOI
Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).
Thandeka Moyo-Gwete,Mashudu Madzivhandila,Zanele Makhado,Frances Ayres,Donald Mhlanga,Brent Oosthuysen,Bronwen E. Lambson,Prudence Kgagudi,Houriiyah Tegally,Arash Iranzadeh,Deelan Doolabh,Lynn Tyers,Lionel Chinhoyi,Mathilda Mennen,Sango Skelem,Gert Marais,Constantinos Kurt Wibmer,Jinal N. Bhiman,Veronica Ueckermann,Theresa M. Rossouw,Michael T. Boswell,Tulio de Oliveira,Carolyn Williamson,Wendy A. Burgers,Ntobeko A B Ntusi,Lynn Morris,Penny L. Moore +26 more
TL;DR: Cross-Reactive Antibody Responses Elicited by the 501Y.V2 Variant Convalescent serum from persons who had recovered from infection with B.1.351, a SARS-CoV-2 variant first identified in SARS as discussed by the authors.
Journal ArticleDOI
SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021.
Jonathan Mandolo,Jacquline Msefula,Marc Henrion,Marc Henrion,Comfort Brown,Brewster Moyo,Aubrey Samon,Thandeka Moyo-Gwete,Thandeka Moyo-Gwete,Zanele Makhado,Zanele Makhado,Frances Ayres,Frances Ayres,Thopisang Motlou,Thopisang Motlou,Nonkululeko Mzindle,Nonkululeko Mzindle,Newton Kalata,Adamson S Muula,Gaurav Kwatra,Gaurav Kwatra,Natasha Nsamala,Andrew Likaka,Thom Mfune,Penny L. Moore,Penny L. Moore,Bridon M'baya,Neil French,Robert S. Heyderman,Todd D. Swarthout,Todd D. Swarthout,Kondwani C Jambo,Kondwani C Jambo,Kondwani C Jambo +33 more
TL;DR: In this article, the authors measured the seroprevalence of anti-SARS-CoV-2 antibodies among randomly selected blood transfusion donor sera in Malawi from January 2020 to July 2021 using a cross-sectional study design.
Posted ContentDOI
SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies
Thandeka Moyo-Gwete,Thandeka Moyo-Gwete,Mashudu Madzivhandila,Zanele Makhado,Frances Ayres,Donald Mhlanga,Brent Oosthuysen,Bronwen E. Lambson,Bronwen E. Lambson,Prudence Kgagudi,Houriiyah Tegally,Arash Iranzadeh,Deelan Doolabh,Lynn Tyers,Lionel Chinhoyi,Mathilda Mennen,Sango Skelem,Gert Marais,Gert Marais,Constantinos Kurt Wibmer,Jinal N. Bhiman,Jinal N. Bhiman,Veronica Ueckermann,Theresa M. Rossouw,Michael T. Boswell,Tulio de Oliveira,Tulio de Oliveira,Tulio de Oliveira,Carolyn Williamson,Carolyn Williamson,Wendy A. Burgers,Ntobeko A B Ntusi,Lynn Morris,Lynn Morris,Lynn Morris,Penny L. Moore,Penny L. Moore,Penny L. Moore +37 more
TL;DR: In this article, the antibody response to the 501Y.V2 variant was examined in a cohort of patients hospitalized with COVID-19 in early 2021 - when over 90% of infections in South Africa were attributed to 501YV2.